Cite
HARVARD Citation
Dimopoulos, M. et al. (n.d.). Carfilozomib versus bortezomib for relapsed or refractory myeloma – Authors' reply. Lancet oncology. 17 (4), pp. e126-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Dimopoulos, M. et al. (n.d.). Carfilozomib versus bortezomib for relapsed or refractory myeloma – Authors' reply. Lancet oncology. 17 (4), pp. e126-. [Online].